Publication Name	World Journal of Gastroenterology
Manuscript ID	20321
Country	Australia

Received	2015-06-01 17:48
Peer-Review Started	2015-06-03 09:07
To Make the First Decision	2015-06-23 15:17
Return for Revision	2015-06-27 17:07
Revised	2015-07-14 17:21
Second Decision	2015-09-13 22:25
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2015-09-15 13:55
Articles in Press	2015-09-15 13:55
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-10-10 13:39
Publish the Manuscript Online	2015-10-23 15:45

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Topic Highlights
Article Title	How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?
Manuscript Source	Invited Manuscript
All Author List	Mark G Ward, Peter M Irving and Miles P Sparrow
Funding Agency and Grant Number
Corresponding Author	Dr. Miles P Sparrow, Department of Gastroenterology, The Alfred Hospital, Melbourne 3004, Australia. m.sparrow@alfred.org.au
Key Words	Inflammatory bowel disease; Thiopurines; Drug monitoring; Tumor necrosis factor-alpha; Com­bination therapy
Core Tip	Clinicians managing inflammatory bowel disease frequently have to decide whether to use anti-tumor necrosis factor (anti-TNF) therapy alone or in combination with immunomodulators (IM), which requires an assessment of patient factors and the risk/benefit profile of each treatment strategy. Once a decision is made to use combination therapy, questions on how best to optimize IMs must be addressed. Thiopurines, rather than methotrexate, (MTX) are more efficacious and easier to administer, whereas in certain population groups, MTX may be safer. The effective dose of IM may be lower in combination therapy and combination therapy is probably most important in the first 12 mo of treatment. Withdrawing IMs is best done when the patient is in deep remission, ideally supported by the use of therapeutic drug monitoring of anti-TNFs.
Publish Date	2015-10-23 15:45
Citation	Ward MG, Irving PM, Sparrow MP. How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease? World J Gastroenterol 2015; 21(40): 11331-11342
URL	http://www.wjgnet.com/1007-9327/full/v21/i40/11331.htm
DOI	http://dx.doi.org/10.3748/wjg.v21.i40.11331

Full Article (PDF)	WJG-21-11331.pdf
Full Article (Word)	WJG-21-11331.doc
Manuscript File	20321-Review.docx
Answering Reviewers	20321-Answering reviewers.pdf
Audio Core Tip	20321-Audio core tip.wav
Conflict-of-Interest Disclosure Form	20321-Conflict-of-interest statement.pdf
Copyright License Agreement	20321-Copyright assignment.pdf
Peer-review Report	20321-Peer-review(s).pdf
Scientific Misconduct Check	20321-Scientific misconduct check.pdf
Scientific Editor Work List	20321-Scientific editor work list.pdf